Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | RORC | P51449 | 1/20 | 0.50 |
| ▸ | MLYCD | O95822 | 8/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 8/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 7/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6484353 | 0.86 | LMNA (0.61) | LMNAMLYCDNR1H3NR1H2SMN1; SMN2 | |
| SCHEMBL6485940 | 0.84 | LMNA (0.59) | LMNARORCMLYCDNR1H3NR1H2 | |
| SCHEMBL6488084 | 0.80 | NR1H2 (0.67) | LMNARORCMLYCDNR1H3NR1H2 | |
| SCHEMBL6501262 | 0.80 | NR1H2 (0.55) | LMNAMLYCDNR1H3NR1H2 | |
| SCHEMBL6486223 | 0.80 | NR1H2 (0.54) | LMNARORCMLYCDNR1H3NR1H2 | |
| SCHEMBL6485130 | 0.80 | LMNA (0.67) | LMNAMLYCDNR1H3NR1H2SMN1; SMN2 | |
| SCHEMBL6486621 | 0.80 | NR1H2 (0.51) | LMNAMLYCDNR1H3NR1H2PPARG | |
| SCHEMBL6486856 | 0.78 | NR1H2 (0.52) | LMNAMLYCDNR1H3NR1H2 | |
| SCHEMBL6502044 | 0.77 | NR1H2 (0.51) | LMNAMLYCDNR1H3NR1H2 | |
| SCHEMBL2949034 | 0.77 | PPARG (0.47) | LMNAPPARGSMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900244-B2 | Anilino liver X-receptor modulators | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | claimed |
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | PHARMACIA CORPORATION | 2004-05-06 | — | — | US | claimed |
| US-6900244-B2 | Anilino liver X-receptor modulators | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | PHARMACIA CORPORATION | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087632-A1 | Controlling metabolism of lipids, cholesterol | NR1H2, NR1H3, SREBF1 | LMNA 2466/4885RORC 129/4885MLYCD 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.